Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Preventive MedicineROCO:6810 -1.18%52 Days Payable is 111.22 as of Dec. 2025, which is 57% below its 10-year median of 258.08. GuruFocus rates ROCO:6810 with a GF Score™ of 52/100 and a GF Value™ of NT$27.53 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, Bio Preventive Medicine ranks better than 57.33% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6810 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Bio Preventive Medicine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Preventive Medicine Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio Preventive Medicine's Days Payable distribution charts can be found below:
* The bar in red indicates where Bio Preventive Medicine's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bio Preventive Medicine's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Preventive Medicine (ROCO:6810) has a Days Payable of 111.22 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio Preventive Medicine and its competitors. This is 57% below median its historical median of 258.08. Over the past decade, Bio Preventive Medicine's Days Payable has ranged from 98.72 to 548.96. According to the industry distribution chart, Bio Preventive Medicine ranks #300 out of 703 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Bio Preventive Medicine's Days Payable too high?
Bio Preventive Medicine's current Days Payable of 111.22 is 57% below median its 10-year median of 258.08. Over the past 10 years, this metric has ranged from a low of 98.72 to a high of 548.96. The Biotechnology industry median Days Payable is 112.61. Bio Preventive Medicine's value of 111.22 is 1.2% below this industry median. Based on the distribution chart, Bio Preventive Medicine ranks #300 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bio Preventive Medicine has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio Preventive Medicine's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio Preventive Medicine ranks #300 out of 703 companies for Days Payable. This puts Bio Preventive Medicine in the upper half of its industry. The industry median Days Payable is 112.61. Bio Preventive Medicine's value of 111.22 is 1.2% below this benchmark. Historically, Bio Preventive Medicine's own Days Payable has ranged from 98.72 to 548.96 over the past decade. While the company's 10-year median is 258.08 vs. the industry median of 112.61, Bio Preventive Medicine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.61, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Preventive Medicine's current Days Payable of 111.22 is 1.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio Preventive Medicine and its competitors. For the Biotechnology industry, the median Days Payable is 112.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Preventive Medicine's current Days Payable is 111.22, which is 57% below median its own 10-year median of 258.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Preventive Medicine stock overvalued right now?
Based on GuruFocus' analysis, Bio Preventive Medicine (ROCO:6810) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.53, compared to a current price of NT$21.00 — trading 23.7% below its estimated fair value. The current Days Payable is 111.22, which is 57% below median its 10-year median of 258.08 and 1.2% below the Biotechnology industry median of 112.61. Bio Preventive Medicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bio Preventive Medicine (ROCO:6810), the current Days Payable is 111.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio Preventive Medicine (ROCO:6810) Overvalued in 2026?
Based on GuruFocus' analysis, Bio Preventive Medicine stock appears to be undervalued.
The current stock price of NT$21.00 is trading 23.7% below its estimated GF Value™ of NT$27.53.
GuruFocus considers Bio Preventive Medicine to be Modestly Undervalued.
Key valuation signals for ROCO:6810:
Days Payable: 111.22 (57% below median its 10-year median of 258.08)
GF Value™: NT$27.53 vs. price of NT$21.00 (23.7% below fair value)
Industry Position: 1.2% below the Biotechnology median (#300 of 703)
No single metric tells the full story. See the ROCO:6810 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio Preventive Medicine Corp is a clinical-stage biotech company, focusing on the early detection and prevention of diseases specialty of those high value-added molecular diagnostic products.
52GF Score
Get the complete analysis for ROCO:6810
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6810 has been successfully added to your 
